The Stokes-Adams syndrome.
D000219:Adams-Stokes Syndrome / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001015:Aortic Arch Syndromes / Q000175:diagnosis; D001285:Atropine / Q000627:therapeutic use; D001341:Autonomic Nervous System / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002740:Chlorothiazide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004071:Digitalis Glycosides / Q000627:therapeutic use; D006327:Heart Block / Q000150:complications; D006329:Heart Conduction System / Q000503:physiopathology; D006330:Heart Defects, Congenital / Q000175:diagnosis; D006801:Humans; D007024:Hypotension, Orthostatic / Q000175:diagnosis; D010138:Pacemaker, Artificial; D011660:Pulmonary Heart Disease / Q000175:diagnosis; D013575:Syncope / Q000175:diagnosis; D013614:Tachycardia, Paroxysmal / Q000150:complications; D014693:Ventricular Fibrillation / Q000150:complications
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000697:Central Nervous System Stimulants; D004071:Digitalis Glycosides; D002740:Chlorothiazide; D001285:Atropine